CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
Feasibility, Acceptability and Representativeness: Collecting Sociodemographic Data in CCTG Trials
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
CCTG is pleased to announce that the 2026 Annual Spring Meeting of Participants will be held April 24-26, 2026, at the Chelsea Hotel in Toronto.
The Award
In recognition of the critical role played by the CCTG throughout her professional career, Dr. Shepherd is giving back by sharing her Gairdner Award with the CCTG. This award, to be endowed in perpetuity, will recognize excellence in clinical trials and translational research and will be open to all qualified CCTG investigators and post graduate trainees working on CCTG research projects.Each award will be $1000 and offered twice a year.
Eligibility
Three new publications from the CCTG Committee on Economic Analysis
CCTG would like to welcome our new Senior Investigator, Dr. James Taylor.
iRECIST training has been a recommended component of immuno-oncology (IO) protocol training documentation in the CCTG Site Training Utility (STU) since 2017. We have recently updated the iRECIST training slides in STU and as of Thursday July 18, 2019, documentation of iRECIST training is now mandatory for Qualified Investigators (QI) participating on new IO trials. In addition to new studies, some recently opened/actively accruing/planned studies will also require documentation of this training for the QI. These trials are: HN9, I227, I238 and I239 (planned).
BRC7 trial has been centrally activated, this is a Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Post Progression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker Signature-driven Analysis
Activation Date: July 10, 2019 NCT Registration ID: NCT03793179
There is still time to register for the next CCTG New Investigator Clinical Trials Course (NICTC) being held August 7th to the 9th at the Donald Gordon Centre in Kingston, Ontario.
The NICTC is an important component of the group mandate to provide and facilitate investigator education and training. The major goal of the course is to familiarize new investigators from across the country with the essentials of clinical trial conduct in the Canadian research environment.
CCTG’s Central Operations and Statistics Office is located in the Cancer Research Institute at Queen’s University, with in-house faculty researchers that include clinician scientists, researchers in community health and epidemiology, and biostatisticians. There are currently a number of key potions open on our team - Acting Manager, Office of Clinical Trials Management, Senior Investigator, Study Coordinator, Regulatory Affairs Team Leader, Regulatory Affairs Coordinator, Monitor/Auditor.
Earlier this year Dr. Yee Ung stepped down from his position as the co-chair of the CCTG Lung Disease Site committee. The group convened a selection committee to choose a radiation oncologist as the new co-chair, over several months the committee solicited applications and interviewed several candidates. The members of the selection committee were: Drs. Penny Bradbury, Matthew Parliament, Andrea Bezjak, Yee Ung, and Joe Pater.
